Ensol Biosciences Inc. announced that it has received KRW 6.9999856 billion in funding from Korea Investment & Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm, Samsung Securities Co. Ltd., Investment Arm
January 15, 2021
Share
On January 15, 2021, Ensol Biosciences Inc. (XKON:A140610) closed the transaction.
Ensol Biosciences Inc. is a Korea-based company mainly engaged in the production and sale of pharmaceuticals. The Company is involved in the development and sale of drugs for degenerative disc disease (DDD), osteoarthritis, triple negative breast cancer (TNBC), Alzheimer's disease (AD) and type I diabetes. In addition, it also produces and sells drugs for animal and provides bio big data analysis services. The drugs for Animal include drugs for animal osteoarthritis, as well as animal anticancer, among others. The bio big data analysis services are provided by knowledge-based in silico drug discovery (KISDD) platform and Ensol trans-omics network system (ETONS).
Ensol Biosciences Inc. announced that it has received KRW 6.9999856 billion in funding from Korea Investment & Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm, Samsung Securities Co. Ltd., Investment Arm